Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - sodium (s)-lactate, quantity: 7.85 g/l - solution, irrigation - excipient ingredients: water for injections; sodium bicarbonate - for use as a peritoneal dialysis solution in the management of end stage renal disease and acute renal failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - sodium (s)-lactate, quantity: 7.85 g/l - solution, irrigation - excipient ingredients: water for injections; sodium bicarbonate - for use as a peritoneal dialysis solution in the management of end stage renal disease and acute renal failure.

Malta - English - Medicines Authority

gambro lundia ab - sodium chloride, sodium hydrogen, carbonate - solution for haemofiltration - sodium chloride 6.45 gram(s) ; sodium hydrogen carbonate 3.09 gram(s) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

gambro lundia ab - magnesium chloride, hexahydrate, sodium chloride, sodium hydrogen, carbonate, lactic acid, calcium chloride, dihydrate, potassium chloride, glucose anhydrous - solution for haemofiltration - magnesium chloride hexahydrate 0.102 millimole(s)/litre ; sodium chloride 6.128 millimole(s)/litre ; sodium hydrogen carbonate 2.936 millimole(s)/litre ; lactic acid 0.27 millimole(s)/litre ; calcium chloride dihydrate 0.257 millimole(s)/litre ; potassium chloride 0.149 millimole(s)/litre ; glucose anhydrous 1.1 millimole(s)/litre - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - sodium chloride, sodium hydrogen, carbonate - solution for haemofiltration - sodium chloride 6.45 g sodium hydrogen carbonate 3.09 g - blood substitutes and perfusion solutions

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 6.43 g/l; potassium chloride, quantity: 1.19 g/l; magnesium chloride hexahydrate, quantity: 3.25 g/l; calcium chloride dihydrate, quantity: 0.176 g/l - solution - excipient ingredients: water for injections; hydrochloric acid - other conditions: the ph of the solution must be adjusted to 7.4 to 7. 8 with 10ml of sodium bicarbonate 8.4% w/v injection bp (not supplied) before use. indications: following ph adjustment with 10ml of sodium bicarbonate 8.4% w/v injection bp, cardioplegia "a" solution is used in combination with ischaemia and hypothermia to induce cardiac arrest during open heart surgery and to preserve the myocardium during asystole.

United States - English - NLM (National Library of Medicine)

fresenius kabi norge as - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 80 mg in 1 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.  when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant.  however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

United States - English - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.  when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant.  however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.